N2-[4,6-bis(4-ethylpiperazin-1-yl)pyrimidin-2-yl]-N1-(7-chloroquinolin-4-yl)ethane-1,2-diamine
Structure Info
- Chemspace ID
- CSSS14880530380 (In-Stock Screening Compounds)
- IUPAC Name
- N2-[4,6-bis(4-ethylpiperazin-1-yl)pyrimidin-2-yl]-N1-(7-chloroquinolin-4-yl)ethane-1,2-diamine
- Mol formula
- C27H38ClN9
- Mol weight
- 524 Da
- Catalog Number(s)
- 39453, HY-155659, T83894
- Copy structure to query editor
- SMILES
- INCHI
- INCHI key
- MOL
Properties
- LogP
- 4.05
- Heavy atoms count
- 37
- Rotatable bond count
- 9
- Number of rings
- 5
- Carbon bond saturation, Fsp3
- 0.518
- Polar surface area (Å)
- 76
- Hydrogen bond acceptors count
- 9
- Hydrogen bond donors count
- 2
- Zoom the structure
- CSSS14880530380
Items Overall 17 items from 3 suppliers
| Supplier | Lead time | Ships from | Purity | Pack | Price, $ | Qty |
|---|---|---|---|---|---|---|
| Cayman Chemical Company, Inc | 10 days | United States To: | 90 | 500 ug | 25.52 | |
| Cayman Chemical Company, Inc | 10 days | United States To: | 90 | 1 mg | 37.84 | |
| Cayman Chemical Company, Inc | 10 days | United States To: | 90 | 5 mg | 161.92 | |
| MedChemExpress | 10 days | United States To: | 99 | 1 mg | 48.00 | |
| MedChemExpress | 10 days | United States To: | 99 | 5 mg | 167.00 | |
| MedChemExpress | 10 days | United States To: | 99 | 10 mg | 275.00 | |
| MedChemExpress | 10 days | United States To: | 99 | 25 mg | 550.00 | |
| MedChemExpress | 10 days | United States To: | 99 | 50 mg | 900.00 | |
| MedChemExpress | 10 days | United States To: | 99 | 100 mg | 1,440.00 | |
| MedChemExpress | 10 days | United States To: | 99 | 1 ml | 193.00 | |
Description: Names: 4A7C-301; Product Description: 4A7C-301 is a blood-brain barrier-permeable Nurr1 agonist, with IC50 values of 48.22 nM and 107.71 nM for binding to Nurr1-LBD in the [3H]-CQ competition assay and TR-FRET assay, respectively. The EC50 of 4A7C-301 for activating Nurr1 transcriptional activity is 6.53 μM, and its EC50 in N27-A dopaminergic cells is approximately 0.2 μM. 4A7C-301 binds directly to Nurr1-LBD, enhances the transcriptional function of Nurr1, and restores the reduction of Nurr1 protein induced by MPP or αSyn. 4A7C-301 alleviates oxidative stress and mitochondrial dysfunction, protects midbrain dopaminergic neurons, inhibits microglial activation, and restores impaired autophagic flux. 4A7C-301 can be used in studies related to neuroprotection and Parkinson's disease; Target: Nuclear Hormone Receptor 4A/NR4A | ||||||
| MedChemExpress EU | 10 days | Sweden To: | 99 | 1 mg | 48.00 | |
| MedChemExpress EU | 10 days | Sweden To: | 99 | 5 mg | 167.00 | |
| MedChemExpress EU | 10 days | Sweden To: | 99 | 10 mg | 275.00 | |
| MedChemExpress EU | 10 days | Sweden To: | 99 | 25 mg | 550.00 | |
| MedChemExpress EU | 10 days | Sweden To: | 99 | 50 mg | 900.00 | |
| MedChemExpress EU | 10 days | Sweden To: | 99 | 100 mg | 1,440.00 | |
| MedChemExpress EU | 10 days | Sweden To: | 99 | 1 ml | 193.00 | |
Description: Names: 4A7C-301; Product Description: 4A7C-301 is a blood-brain barrier-permeable Nurr1 agonist, with IC50 values of 48.22 nM and 107.71 nM for binding to Nurr1-LBD in the [3H]-CQ competition assay and TR-FRET assay, respectively. The EC50 of 4A7C-301 for activating Nurr1 transcriptional activity is 6.53 μM, and its EC50 in N27-A dopaminergic cells is approximately 0.2 μM. 4A7C-301 binds directly to Nurr1-LBD, enhances the transcriptional function of Nurr1, and restores the reduction of Nurr1 protein induced by MPP or αSyn. 4A7C-301 alleviates oxidative stress and mitochondrial dysfunction, protects midbrain dopaminergic neurons, inhibits microglial activation, and restores impaired autophagic flux. 4A7C-301 can be used in studies related to neuroprotection and Parkinson's disease; Target: Nuclear Hormone Receptor 4A/NR4A | ||||||
For a custom pack size or bulk
please drop us a line:Enquire
please drop us a line:Enquire